DGLA (Dihomo-Gamma-Linolenic Acid)

DGLA (Dihomo-Gamma-Linolenic Acid) is an omega-6 fatty acid that produces anti-inflammatory prostaglandin E1 (PGE1) through cyclooxygenase conversion. Unlike other omega-6 fatty acids, DGLA reduces inflammation by competing with arachidonic acid for enzyme binding sites.

Origin & History

DGLA, or dihomo-gamma-linolenic acid, is an omega-6 fatty acid found in small amounts in animal fats and some plant oils. It is produced in the body from GLA and plays a role in anti-inflammatory processes.

Historical & Cultural Context

DGLA has been less studied than other omega-6 fatty acids but is gaining attention for its unique properties and potential health benefits.

Health Benefits

- Supports anti-inflammatory responses in the body. DGLA reduces inflammatory markers by up to 30%, promoting overall wellness. - Aids in maintaining joint health and reducing pain. It decreases joint inflammation, enhancing mobility and comfort. - Supports skin health by reducing acne and improving texture. DGLA's anti-inflammatory properties soothe and smooth the skin. - Enhances immune system function. It boosts the production of anti-inflammatory cytokines, strengthening defenses. - Supports cardiovascular health by improving blood vessel function. DGLA helps maintain healthy blood pressure levels. - May assist in managing symptoms of PMS. It regulates prostaglandin production, reducing menstrual discomfort. - Promotes mental well-being by supporting neurotransmitter function. DGLA aids in mood regulation and cognitive clarity.

How It Works

DGLA converts to prostaglandin E1 (PGE1) via cyclooxygenase-1 and cyclooxygenase-2 enzymes, producing anti-inflammatory effects. It competes with arachidonic acid for delta-5 desaturase enzyme binding, reducing pro-inflammatory arachidonic acid metabolism. DGLA also activates peroxisome proliferator-activated receptor gamma (PPAR-γ), further suppressing inflammatory gene expression.

Scientific Research

Preliminary research, including in vitro studies, suggests DGLA's potential in supporting anti-inflammatory and cardiovascular health. Its role in the metabolism of GLA is being explored.

Clinical Summary

Small-scale studies with 20-60 participants show DGLA supplementation reduces inflammatory markers like IL-6 and TNF-α by 20-30% over 8-12 weeks. Clinical trials in rheumatoid arthritis patients demonstrate modest improvements in joint pain scores and morning stiffness. However, most research consists of pilot studies rather than large randomized controlled trials. Evidence is promising but requires larger, longer-term studies to establish definitive therapeutic benefits.

Nutritional Profile

- Contains omega-6 fatty acids, particularly DGLA.
- Acts as an intermediate in the metabolism of GLA.
- Found in small amounts in animal fats and some plant oils.

Preparation & Dosage

Typical dosage ranges from 100 mg to 500 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

GLA, Omega-3 Fatty Acids, Vitamin E

Safety & Interactions

DGLA is generally well-tolerated with mild gastrointestinal upset reported in some users. It may enhance anticoagulant effects of warfarin and increase bleeding risk when combined with blood-thinning medications. Individuals with seizure disorders should use caution as omega-6 fatty acids may lower seizure threshold. Safety during pregnancy and breastfeeding has not been established through adequate clinical studies.